芴甲氧羰基-O-叔丁基-D-苏氨酸 | 138797-71-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苏氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: 芴甲氧羰基-O-叔丁基-D-苏氨酸
• 中文别名: FMOC-O-叔丁基-D-苏氨酸；Fmoc-O-叔丁基-D-苏氨酸；Fmoc-D-Thr(tBu)-OH
• 英文名称: Fmoc-D-Thr(tBu)-OH
• 英文别名: Fmoc-D-Thr(O-t-Bu)-OH；(2R,3S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid
• CAS: 138797-71-4
• 化学式: C₂₃H₂₇NO₅
• mdl: MFCD00080292
• 分子量: 397.471
• InChiKey: LZOLWEQBVPVDPR-VBKZILBWSA-N

物化性质

• 熔点：
  ~130 °C
• 沸点：
  581.7±50.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.391
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• WGK Germany：
  3
• 海关编码：
  2924 29 70
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  | 2-8°C |

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Fmoc-D-Thr(tBu)-OH
CAS-No. : 138797-71-4
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
Not a hazardous substance or mixture according to EC-directives 67/548/EEC or 1999/45/EC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : Fmoc-O-tert-butyl-D-threonine
Formula : C23H27NO5
Molecular Weight : 397,46 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Store under inert gas.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: light yellow
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 130 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

(2S)-2-(((9H-芴-9-基)甲氧基)羰基氨基)-3-(叔丁氧基)丁酸是一种苏氨酸衍生物[1]。

反应信息

• 作为反应物：
  描述：

  芴甲氧羰基-O-叔丁基-D-苏氨酸 在 4-二甲氨基吡啶 、 二乙基异丙基胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.58h， 生成 benzyl N-[9-(fluorenylmethoxycarbonyl)]-D-threoninate
  参考文献：
  名称：

  Solid-Phase Synthesis of O-Linked Glycopeptide Analogues of Enkephalin

  摘要：

  The synthesis of 18 N-alpha -FMOC-amino acid glycosides for solid-phase glycopeptide assembly is reported. The glycosides were synthesized either from the corresponding O'Donnell Schiff bases or from N-alpha -FMOC-amino protected serine or threonine and the appropriate glycosyl bromide using Hanessian's modification of the Koenigs-Knorr reaction. Reaction rates of D-glycosyl bromides (e.g., acetobromoglucose) with the L- and D-forms of serine and threonine are distinctly different and can be rationalized in terms of the steric interactions within the two types of diastereomeric transition states for the D/L and D/D reactant pairs. The N-alpha -FMOC-protected glycosides [monosaccharides Xyl, Glc, Gal, Man, GlcNAc, and GalNAc; disaccharides Gal-beta (1-4)-Gle (lactose), Glc-beta-(1-4)-Glc (cellobiose), and Gal-alpha (1-6)-Glc (melibiose)] were incorporated into 22 enkephalin glycopeptide analogues. These peptide opiates bearing the pharmacophore H-Tyr-c[DCys-Gly-PheDCys]- were designed to probe the significance of the glycoside moiety and the carbohydrate-peptide linkage region in blood-brain barrier (BBB) transport, opiate receptor binding, and analgesia.

  DOI：

  10.1021/jo005712m

文献信息

• γ-Valerolactone (GVL): An eco-friendly anchoring solvent for solid-phase peptide synthesis
  作者：Othman Al Musaimi、Ayman El-Faham、Alessandra Basso、Beatriz G. de la Torre、Fernando Albericio

  DOI：10.1016/j.tetlet.2019.151058

  日期：2019.9

  authorities have imposed restrictions to minimize or even stop its use. It has therefore become imperative to identify environmentally benign solvents to replace it. Here we report on a bio derived solvent, γ-valerolactone, for the incorporation of the first amino acid onto p-alkoxybenzyl alcohol resin in solid-phase peptide synthesis. Satisfactory loading values (by a spectrophotometric method) were

  由于CH 2 Cl 2的危险性，监管机构已施加限制以最小化或什至停止使用它。因此，必须找到对环境无害的溶剂来替代它。在这里，我们报告了一种生物衍生的溶剂γ-戊内酯，用于在固相肽合成中将第一个氨基酸掺入对烷氧基苄醇树脂中。达到了令人满意的负载值（通过分光光度法）。此外，还检查了外消旋化和二肽形成，发现是可接受的。
• Systemic Antibacterial Activity of Novel Synthetic Cyclic Peptides
  作者：Véronique Dartois、Jorge Sanchez-Quesada、Edelmira Cabezas、Ellen Chi、Chad Dubbelde、Carrie Dunn、Juan Granja、Colleen Gritzen、Dana Weinberger、M. Reza Ghadiri、Thomas R. Parr

  DOI：10.1128/aac.49.8.3302-3310.2005

  日期：2005.8

  Cyclic peptides with an even number of alternatingd,l-α-amino acid residues are known to self-assemble into organic nanotubes. Such peptides previously have been shown to be stable upon protease treatment, membrane active, and bactericidal and to exert antimicrobial activity againstStaphylococcus aureusand other gram-positive bacteria. The present report describes the in vitro and in vivo pharmacology of selected members of this cyclic peptide family. The intravenous (i.v.) efficacy of six compounds with MICs of less than 12 μg/ml was tested in peritonitis and neutropenic-mouse thigh infection models. Four of the six peptides were efficacious in vivo, with 50% effective doses in the peritonitis model ranging between 4.0 and 6.7 mg/kg against methicillin-sensitiveS. aureus(MSSA). In the thigh infection model, the four peptides reduced the bacterial load 2.1 to 3.0 log units following administration of an 8-mg/kg i.v. dose. Activity against methicillin-resistantS. aureuswas similar to MSSA. The murine pharmacokinetic profile of each compound was determined following i.v. bolus injection. Interestingly, those compounds with poor efficacy in vivo displayed a significantly lower maximum concentration of the drug in serum and a higher volume of distribution at steady state than compounds with good therapeutic properties.S. aureuswas unable to easily develop spontaneous resistance upon prolonged exposure to the peptides at sublethal concentrations, in agreement with the proposed interaction with multiple components of the bacterial membrane canopy. Although additional structure-activity relationship studies are required to improve the therapeutic window of this class of antimicrobial peptides, our results suggest that these amphipathic cyclicd,l-α-peptides have potential for systemic administration and treatment of otherwise antibiotic-resistant infections.

  摘要已知具有偶数个交替的 d,l-α-氨基酸残基的环肽可以自组装成有机纳米管。以前的研究表明，这种肽在蛋白酶处理后具有稳定性、膜活性和杀菌性，并对金黄色葡萄球菌和其他革兰氏阳性细菌具有抗菌活性。本报告介绍了该环肽家族部分成员的体外和体内药理学。在腹膜炎和嗜中性粒细胞小鼠大腿感染模型中，对 MIC 小于 12 μg/ml 的六种化合物进行了静脉注射药效测试。在腹膜炎模型中，六种肽中的四种对甲氧西林敏感金黄色葡萄球菌（MSSA）的50%有效剂量为4.0至6.7毫克/千克。在大腿感染模型中，静脉注射 8 毫克/千克的剂量后，四种肽能使细菌量减少 2.1 至 3.0 log 单位。对耐甲氧西林金黄色葡萄球菌的活性与 MSSA 相似。在静脉注射后，测定了每种化合物的小鼠药代动力学特征。有趣的是，与疗效好的化合物相比，体内疗效差的化合物在血清中的最大药物浓度明显较低，稳态分布容积也较高。金黄色葡萄球菌在长期接触亚致死浓度的肽后不易产生自发抗药性，这与所提出的与细菌膜顶盖的多种成分相互作用是一致的。虽然还需要进行更多的结构-活性关系研究来改善这类抗菌肽的治疗窗口，但我们的研究结果表明，这些两性环d,l-α-肽具有全身给药和治疗抗生素耐药性感染的潜力。
• Cysteine protease inhibitors
  申请人：——

  公开号：US20030186962A1

  公开（公告）日：2003-10-02

  of the formula (IV): 1 where: R1=R′C(O), R′SO2, R′=a bicyclic, saturated or unsaturated, 8-12 membered ring system containing 0-4 hetero atoms selected from S, O and N, which is optionally substituted with up to four substituents independently selected from groups a), b) and c) below; or R′=a monocyclic, saturated or unsaturated, 5-7 membered ring containing 0-3 hetero atoms selected from S, O and N, which monocyclic ring bears at least one substituent selected from group a) and/or c) and which may optionally bear one or two further substituents selected from group b); R4=H, C1-7-alkyl, Ar-C1-7-alkyl, Ar, C3-7-cycloalkyl; C2-7alkenyl; R3=C1-7-alkyl, C2-C7 alkenyl, C2-C7 alkenyl, C3-7-cycloalkyl, Ar-C1-7-alkyl, Ar; R5=C1-7-alkyl, halogen, Ar-C1-7-alkyl, C1-3-alkyl-CONR3R4 or a bulky amine R6 is H, C1-7-alkyl, Ar-C1-7-alkyl, C1-3-alkyl-SO2-R ix , C1-3-alkyl-C(O)—NHR ix or CH 2 XAr q is 0 or 1 have utility as inhibitors of cysteine proteases such as cathepsin K and falcipain.

  公式（IV）的翻译如下： 其中： R1=R′C(O)，R′SO2， R′=含有0-4个来自S、O和N的杂原子的8-12元环系统，可以选择饱和或不饱和的双环，可选地取代最多四个从下面的a)、b)和c)组中独立选择的取代基；或 R′=含有0-3个来自S、O和N的杂原子的5-7元环，该单环至少带有从a)组和/或c)组中选择的一个取代基，并且可选地带有从b)组中选择的一个或两个进一步的取代基； R4=H，C1-7-烷基，Ar-C1-7-烷基，Ar，C3-7-环烷基；C2-7-烯基； R3=C1-7-烷基，C2-C7烯基，C2-C7烯基，C3-7-环烷基，Ar-C1-7-烷基，Ar； R5=C1-7-烷基，卤素，Ar-C1-7-烷基，C1-3-烷基-CONR3R4或体积庞大的胺 R6为H，C1-7-烷基，Ar-C1-7-烷基，C1-3-烷基-SO2-R ix ，C1-3-烷基-C(O)—NHR ix 或CH 2 XAr q为0或1 具有作为半胱氨酸蛋白酶抑制剂的实用性，例如卡特普辛K和疟原虫蛋白酶。
• Examination of the active secondary structure of the peptide 101.10, an allosteric modulator of the interleukin-1 receptor, by positional scanning using β-amino γ-lactams
  作者：Nicolas Boutard、Stéphane Turcotte、Kim Beauregard、Christiane Quiniou、Sylvain Chemtob、William D. Lubell

  DOI：10.1002/psc.1337

  日期：2011.4

  activity of the peptide allosteric modulator of the interleukin‐1 receptor 101.10 (D‐Arg‐D‐Tyr‐D‐Thr‐D‐Val‐D‐Glu‐D‐Leu‐D‐Ala‐NH2) has been studied using (R)‐ and (S)‐Bgl residues. Twelve Bgl peptides were synthesized using (R)‐ and (S)‐cyclic sulfamidate reagents derived from L‐ and D‐aspartic acid in an optimized Fmoc‐compatible protocol for efficient lactam installment onto the supported peptide resin. Examination

  白介素-1受体101.10（的肽变构调节剂的构象和生物活性之间的关系d是-Arg- d -Tyr- d -Thr- d -Val- d -Glu- d -Leu- d -Ala-NH 2）已使用（R）-和（S）-Bgl残基进行了研究。使用衍生自L和D的（R）-和（S）-环氨基磺酸盐试剂合成了十二种Bgl肽优化的Fmoc兼容方案中的天冬氨酸，可有效地将内酰胺安装到支持的肽树脂上。检查这些（R）-和（S）-Bgl 101.10类似物具有使用新型荧光测定法抑制IL-1β诱导的胸腺细胞增殖的潜力，揭示了某些类似物相对于母体肽101.10表现出保留并提高了效力。根据先前的报道，Bgl残基可以稳定肽中的II'β-turn-like构象，对选定的化合物进行了CD光谱分析，以鉴定肽生物学活性所必需的二级结构。结果表明，亲本肽的中央残基周围存在折叠可能对活性很重要。版权所有©2011欧洲肽协会和John Wiley＆Sons，Ltd
• [EN] TUMOUR-TARGETING PEPTIDE VARIANTS<br/>[FR] VARIANTS PEPTIDIQUES CIBLANT DES TUMEURS
  申请人：CANCER RESEARCH TECH LTD

  公开号：WO2018197490A1

  公开（公告）日：2018-11-01

  The present invention provides a peptide that selectively binds ανβ6 integrin, the peptide having an amino acid sequence comprising the motif X1BnRGDLX2X3X4 ZmX5, wherein X1 is any D-amino acid, Bn is a sequence of any n amino acids, which may be natural or unnatural, D- or L-, and may be the same or different, wherein n is a number between 1 and 10, X2 and X3 are independently selected from any amino acid, X4 is Leu or Ile, Zm is a sequence of any m amino acids, which may be natural or unnatural, D- or L-, and may be the same or different, wherein m is a number between 1 and 10, X5 is any L- or D-amino acid. Also provided are conjugates comprising said peptide, pharmaceutical compositions comprising said peptide or said conjugates, and uses of said peptide, conjugate or composition, for example, in the treatment, imaging and/or diagnosis of an ανβ6- expressing tumour in a mammalian subject.

  本发明提供了一种选择性结合ανβ6整合素的肽，该肽具有氨基酸序列，包括基序X1BnRGDLX2X3X4 ZmX5，其中X1是任何D-氨基酸，Bn是任何n个氨基酸的序列，可以是天然的或非天然的，D-或L-，可以相同也可以不同，其中n是1到10之间的数字，X2和X3分别选自任何氨基酸，X4是Leu或Ile，Zm是任何m个氨基酸的序列，可以是天然的或非天然的，D-或L-，可以相同也可以不同，其中m是1到10之间的数字，X5是任何L-或D-氨基酸。还提供了包括所述肽的结合物，包括所述肽或所述结合物的药物组合物，以及所述肽，结合物或组合物的用途，例如，在治疗、成像和/或诊断哺乳动物主体中表达ανβ6的肿瘤。